{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,9]],"date-time":"2026-04-09T13:57:27Z","timestamp":1775743047277,"version":"3.50.1"},"reference-count":148,"publisher":"The Endocrine Society","issue":"4","license":[{"start":{"date-parts":[[2023,1,26]],"date-time":"2023-01-26T00:00:00Z","timestamp":1674691200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2023,2,9]]},"abstract":"<jats:title>Abstract<\/jats:title>\n               <jats:p>Primary hyperparathyroidism (PHPT) is classically characterized by hypercalcemia with elevated or inappropriately normal parathyroid hormone (PTH) levels. Elevated PTH levels in the presence of normal calcium levels are not infrequently found during the evaluation of metabolic bone disorders or kidney stone disease. This can be caused by secondary hyperparathyroidism (SHPT) or normocalcemic primary hyperparathyroidism (NPHPT). NPHPT is due to autonomous parathyroid function whereas SHPT is caused by a physiologic stimulation to PTH secretion. Many medical conditions and medications can contribute to SHPT, and differentiation between SHPT and NPHPT may be difficult. Cases are presented to illustrate examples. In this paper, we review the distinction between SHPT and NPHPT as well as end organ effects of NPHPT and outcomes of surgery in NPHPT. We suggest that the diagnosis of NPHPT be made only after careful exclusion of causes of SHPT and consideration of medications that can increase PTH secretion. Further, we advise a conservative approach to surgery in NPHPT.<\/jats:p>","DOI":"10.1210\/jendso\/bvad013","type":"journal-article","created":{"date-parts":[[2023,2,13]],"date-time":"2023-02-13T05:42:00Z","timestamp":1676266920000},"source":"Crossref","is-referenced-by-count":19,"title":["The Eucalcemic Patient With Elevated Parathyroid Hormone Levels"],"prefix":"10.1210","volume":"7","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-6266-1029","authenticated-orcid":false,"given":"Joseph L","family":"Shaker","sequence":"first","affiliation":[{"name":"Department of Medicine and Division of Endocrinology and Molecular Medicine, Medical College of Wisconsin , Milwaukee, WI , USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9822-7881","authenticated-orcid":false,"given":"Robert A","family":"Wermers","sequence":"additional","affiliation":[{"name":"Department of Medicine and Division of Endocrinology, Diabetes, Metabolism and Nutrition, Mayo Clinic , Rochester, MN , USA"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"80","published-online":{"date-parts":[[2023,1,26]]},"reference":[{"issue":"3","key":"2023021305415034500_bvad013-B1","doi-asserted-by":"publisher","first-page":"1122","DOI":"10.1210\/jc.2012-4022","article-title":"Incidence and prevalence of primary hyperparathyroidism in a racially mixed population","volume":"98","author":"Yeh","year":"2013","journal-title":"J Clin Endocrinol Metab"},{"key":"2023021305415034500_bvad013-B2","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.bone.2014.12.003","article-title":"Secular trends in the incidence of primary hyperparathyroidism over five decades (1965-2010)","volume":"73","author":"Griebeler","year":"2015","journal-title":"Bone"},{"issue":"11","key":"2023021305415034500_bvad013-B3","doi-asserted-by":"publisher","first-page":"2293","DOI":"10.1002\/jbmr.4677","article-title":"Evaluation and management of primary hyperparathyroidism: summary statement and guidelines from the fifth international workshop","volume":"37","author":"Bilezikian","year":"2022","journal-title":"J Bone Mineral Res"},{"issue":"11","key":"2023021305415034500_bvad013-B4","doi-asserted-by":"publisher","first-page":"2330","DOI":"10.1002\/jbmr.4679","article-title":"Classical and nonclassical manifestations of primary hyperparathyroidism","volume":"37","author":"El-Hajj Fuleihan","year":"2022","journal-title":"J Bone Mineral Res"},{"issue":"6","key":"2023021305415034500_bvad013-B5","doi-asserted-by":"publisher","first-page":"615","DOI":"10.1210\/js.2017-00104","article-title":"Longitudinal assessment of PTH in community-dwelling older women\u2014elevations are not associated with mortality","volume":"1","author":"Buchebner","year":"2017","journal-title":"J Endocr Soc"},{"issue":"2","key":"2023021305415034500_bvad013-B6","doi-asserted-by":"publisher","first-page":"399","DOI":"10.1210\/jcem.77.2.8345044","article-title":"Pulsatile secretion of parathyroid hormone in normal young subjects: assessment by deconvolution analysis","volume":"77","author":"Samuels","year":"1993","journal-title":"J Clin Endocrinol Metab"},{"issue":"11","key":"2023021305415034500_bvad013-B7","doi-asserted-by":"publisher","first-page":"3304","DOI":"10.1210\/jcem.80.11.7593443","article-title":"Role of parathyroid hormone in mediating nocturnal and age-related increases in bone resorption","volume":"80","author":"Ledger","year":"1995","journal-title":"J Clin Endocrinol Metab"},{"issue":"1","key":"2023021305415034500_bvad013-B8","doi-asserted-by":"publisher","first-page":"69","DOI":"10.1210\/jcem-72-1-69","article-title":"Circadian variation in ionized calcium and intact parathyroid hormone: evidence for sex differences in calcium homeostasis","volume":"72","author":"Calvo","year":"1991","journal-title":"J Clin Endocrinol Metab"},{"issue":"3","key":"2023021305415034500_bvad013-B9","doi-asserted-by":"publisher","first-page":"384","DOI":"10.1016\/0002-9343(69)90222-8","article-title":"Normocalcemic primary hyperparathyroidism","volume":"47","author":"Wills","year":"1969","journal-title":"Am J Med"},{"issue":"8","key":"2023021305415034500_bvad013-B10","doi-asserted-by":"publisher","first-page":"3001","DOI":"10.1210\/jc.2006-2802","article-title":"Normocalcemic primary hyperparathyroidism: further characterization of a new clinical phenotype","volume":"92","author":"Lowe","year":"2007","journal-title":"J Clin Endocrinol Metab"},{"issue":"1","key":"2023021305415034500_bvad013-B11","doi-asserted-by":"publisher","first-page":"33","DOI":"10.1016\/j.jocd.2012.12.001","article-title":"Normocalcemic primary hyperparathyroidism","volume":"16","author":"Cusano","year":"2013","journal-title":"J Clin Densitom"},{"issue":"6","key":"2023021305415034500_bvad013-B12","doi-asserted-by":"publisher","first-page":"837","DOI":"10.1016\/j.beem.2018.09.009","article-title":"Management of normocalcemic primary hyperparathyroidism","volume":"32","author":"Cusano","year":"2018","journal-title":"Best Pract Res Clin Endocrinol Metab"},{"issue":"8","key":"2023021305415034500_bvad013-B13","doi-asserted-by":"publisher","first-page":"e10391","DOI":"10.1002\/jbm4.10391","article-title":"Normocalcemic hyperparathyroidism: a heterogeneous disorder often misdiagnosed?","volume":"4","author":"Zavatta","year":"2020","journal-title":"JBMR Plus"},{"issue":"5","key":"2023021305415034500_bvad013-B14","doi-asserted-by":"publisher","first-page":"519","DOI":"10.1111\/cen.14315","article-title":"Normocalcaemic primary hyperparathyroidism: an update on diagnostic and management challenges","volume":"93","author":"Dawood","year":"2020","journal-title":"Clin Endocrinol"},{"issue":"6","key":"2023021305415034500_bvad013-B15","doi-asserted-by":"publisher","first-page":"1135","DOI":"10.1016\/j.mcna.2021.05.017","article-title":"Evaluation and management of elevated parathyroid hormone levels in normocalcemic patients","volume":"105","author":"Cusano","year":"2021","journal-title":"Med Clin North Am"},{"issue":"2","key":"2023021305415034500_bvad013-B16","doi-asserted-by":"publisher","first-page":"R33","DOI":"10.1530\/eje-21-1044","article-title":"European expert consensus on practical management of specific aspects of parathyroid disorders in adults and in pregnancy: recommendations of the ESE educational program of parathyroid disorders (PARAT 2021)","volume":"186","author":"Bollerslev","year":"2022","journal-title":"Eur J Endocrinol"},{"issue":"11","key":"2023021305415034500_bvad013-B17","doi-asserted-by":"publisher","first-page":"5348","DOI":"10.1210\/jc.2003-031014","article-title":"\u201cIncipient\u201d primary hyperparathyroidism: a \u201cforme fruste\u201d of an old disease","volume":"88","author":"Silverberg","year":"2003","journal-title":"J Clin Endocrinol Metab"},{"issue":"4","key":"2023021305415034500_bvad013-B18","doi-asserted-by":"publisher","first-page":"761","DOI":"10.1007\/s00268-012-1438-y","article-title":"Surgical management of normocalcemic primary hyperparathyroidism","volume":"36","author":"Wade","year":"2012","journal-title":"World J Surg"},{"issue":"5","key":"2023021305415034500_bvad013-B19","doi-asserted-by":"publisher","first-page":"470","DOI":"10.4158\/ep-2018-0489","article-title":"Biochemical dynamics of untreated primary hyperparathyroidism: an observational study","volume":"25","author":"Yeh","year":"2019","journal-title":"Endocr Pract"},{"issue":"2","key":"2023021305415034500_bvad013-B20","doi-asserted-by":"crossref","first-page":"271","DOI":"10.1172\/JCI100349","article-title":"Studies of calcium and phosphorus metabolism: XVIII. On temporary fluctuations in the level of calcium and inorganic phosphorus in blood serum of normal individuals","volume":"10","author":"Farquharson","year":"1930","journal-title":"J Clin Invest"},{"issue":"1","key":"2023021305415034500_bvad013-B21","doi-asserted-by":"publisher","first-page":"211","DOI":"10.1210\/jcem.79.1.8027229","article-title":"Abnormalities of parathyroid hormone secretion in elderly women that are reversible by short term therapy with 1,25-dihydroxyvitamin D3","volume":"79","author":"Ledger","year":"1994","journal-title":"J Clin Endocrinol Metab"},{"issue":"10","key":"2023021305415034500_bvad013-B22","doi-asserted-by":"publisher","first-page":"4641","DOI":"10.1210\/jc.2002-021404","article-title":"Normocalcemic primary hyperparathyroidism: evidence for a generalized target-tissue resistance to parathyroid hormone","volume":"88","author":"Maruani","year":"2003","journal-title":"J Clin Endocrinol Metab"},{"issue":"2","key":"2023021305415034500_bvad013-B23","doi-asserted-by":"publisher","first-page":"174","DOI":"10.4158\/ep-2019-0325","article-title":"Low free (but not total) 25-hydroxyvitamin D levels in subjects with normocalcemic hyperparathyroidism","volume":"26","author":"Wang","year":"2020","journal-title":"Endocr Pract"},{"issue":"3","key":"2023021305415034500_bvad013-B24","doi-asserted-by":"publisher","first-page":"163","DOI":"10.1055\/s-0035-1559723","article-title":"Clinical expression of calcium sensing receptor polymorphism (A986S) in normocalcemic and asymptomatic hyperparathyroidism","volume":"48","author":"D\u00edaz-Soto","year":"2015","journal-title":"Horm Metab Res"},{"issue":"1","key":"2023021305415034500_bvad013-B25","doi-asserted-by":"publisher","first-page":"134","DOI":"10.1172\/jci107156","article-title":"Evidence for secondary hyperparathyroidism in idiopathic hypercalciuria","volume":"52","author":"Coe","year":"1973","journal-title":"J Clin Invest"},{"issue":"2","key":"2023021305415034500_bvad013-B26","doi-asserted-by":"publisher","first-page":"120","DOI":"10.1016\/j.semnephrol.2008.01.005","article-title":"New insights into the pathogenesis of idiopathic hypercalciuria","volume":"28","author":"Worcester","year":"2008","journal-title":"Semin Nephrol"},{"issue":"2","key":"2023021305415034500_bvad013-B27","doi-asserted-by":"publisher","first-page":"191","DOI":"10.1089\/end.2008.0567","article-title":"Differentiating primary from secondary hyperparathyroidism in stone patients: the \u201cthiazide challenge.\u201d","volume":"23","author":"Eisner","year":"2009","journal-title":"J Endourol"},{"issue":"3","key":"2023021305415034500_bvad013-B28","doi-asserted-by":"publisher","first-page":"1166","DOI":"10.1210\/jc.2015-3964","article-title":"Thiazide-associated hypercalcemia: incidence and association with primary hyperparathyroidism over two decades","volume":"101","author":"Griebeler","year":"2016","journal-title":"J Clin Endocrinol Metab"},{"issue":"1","key":"2023021305415034500_bvad013-B29","doi-asserted-by":"publisher","first-page":"142","DOI":"10.1186\/s12916-019-1380-z","article-title":"Celiac disease: a comprehensive current review","volume":"17","author":"Caio","year":"2019","journal-title":"BMC Med"},{"issue":"4","key":"2023021305415034500_bvad013-B30","doi-asserted-by":"publisher","first-page":"652","DOI":"10.1359\/jbmr.1999.14.4.652","article-title":"Bone loss in celiac disease is related to secondary hyperparathyroidism","volume":"14","author":"Selby","year":"1999","journal-title":"J Bone Miner Res"},{"issue":"6","key":"2023021305415034500_bvad013-B31","doi-asserted-by":"publisher","first-page":"1295","DOI":"10.1128\/cdli.9.6.1295-1300.2002","article-title":"Celiac disease and immunoglobulin A deficiency: how effective are the serological methods of diagnosis?","volume":"9","author":"Kumar","year":"2002","journal-title":"Clin Vaccine Immunol"},{"issue":"1","key":"2023021305415034500_bvad013-B32","doi-asserted-by":"publisher","first-page":"35","DOI":"10.1056\/nejmoa2032441","article-title":"A randomized trial of a transglutaminase 2 inhibitor for celiac disease","volume":"385","author":"Schuppan","year":"2021","journal-title":"N Engl J Med"},{"issue":"1","key":"2023021305415034500_bvad013-B33","doi-asserted-by":"publisher","first-page":"370","DOI":"10.1172\/jci111971","article-title":"Evidence for alteration of the vitamin D-endocrine system in obese subjects","volume":"76","author":"Bell","year":"1985","journal-title":"J Clin Invest"},{"issue":"3","key":"2023021305415034500_bvad013-B34","doi-asserted-by":"publisher","first-page":"798","DOI":"10.1007\/s11695-017-2932-y","article-title":"High incidence of secondary hyperparathyroidism in bariatric patients: comparing different procedures","volume":"28","author":"Wei","year":"2017","journal-title":"Obes Surg"},{"issue":"6","key":"2023021305415034500_bvad013-B35","doi-asserted-by":"publisher","first-page":"2225","DOI":"10.1007\/s11695-020-04453-z","article-title":"Determinants of high parathyroid hormone levels in patients with severe obesity and their relationship with the cardiometabolic risk factors, before and after a laparoscopic sleeve gastrectomy intervention","volume":"30","author":"Ministrini","year":"2020","journal-title":"Obes Surg"},{"issue":"5","key":"2023021305415034500_bvad013-B36","doi-asserted-by":"publisher","first-page":"1320","DOI":"10.1210\/jc.2010-2202","article-title":"Vitamin D and hyperparathyroidism in obesity","volume":"96","author":"Grethen","year":"2011","journal-title":"J Clin Endocrinol Metab"},{"issue":"6","key":"2023021305415034500_bvad013-B37","doi-asserted-by":"publisher","first-page":"638","DOI":"10.1016\/j.soard.2006.09.003","article-title":"Effect of gastric bypass surgery on vitamin D nutritional status","volume":"2","author":"Carlin","year":"2006","journal-title":"Surg Obes Relat Dis"},{"issue":"8","key":"2023021305415034500_bvad013-B38","doi-asserted-by":"publisher","first-page":"1377","DOI":"10.1002\/jbmr.2467","article-title":"Intestinal calcium absorption decreases dramatically after gastric bypass surgery despite optimization of vitamin D status","volume":"30","author":"Schafer","year":"2015","journal-title":"J Bone Miner Res"},{"issue":"3","key":"2023021305415034500_bvad013-B39","doi-asserted-by":"publisher","first-page":"256","DOI":"10.4158\/ep-2017-0072","article-title":"Increased bone turnover in type 2 diabetes patients randomized to bariatric surgery versus medical therapy at 5 years","volume":"24","author":"Crawford","year":"2018","journal-title":"Endocr Pract"},{"issue":"9","key":"2023021305415034500_bvad013-B40","doi-asserted-by":"publisher","first-page":"1256","DOI":"10.1007\/s11695-009-9850-6","article-title":"Comparison of the absorption of calcium carbonate and calcium citrate after Roux-en-Y gastric bypass","volume":"19","author":"Tondapu","year":"2009","journal-title":"Obes Surg"},{"issue":"6","key":"2023021305415034500_bvad013-B41","doi-asserted-by":"publisher","first-page":"734","DOI":"10.1111\/cen.13836","article-title":"Effect of calcium citrate vs calcium carbonate on elevated parathyroid hormone after Roux-en-Y gastric bypass. A double-blinded, randomized trial","volume":"89","author":"Ring Madsen","year":"2018","journal-title":"Clin Endocrinol"},{"issue":"4","key":"2023021305415034500_bvad013-B42","doi-asserted-by":"publisher","first-page":"700","DOI":"10.1007\/s11695-014-1444-2","article-title":"Primary hyperparathyroidism after Roux-en-Y gastric bypass","volume":"25","author":"Chen","year":"2014","journal-title":"Obes Surg"},{"issue":"3","key":"2023021305415034500_bvad013-B43","doi-asserted-by":"publisher","first-page":"155","DOI":"10.1089\/bari.2019.0043","article-title":"Does bariatric surgery increase the formation of parathyroid adenoma?","volume":"15","author":"Keskin","year":"2020","journal-title":"Bariatr Surg Pract Patient Care"},{"issue":"9","key":"2023021305415034500_bvad013-B44","doi-asserted-by":"publisher","first-page":"2844","DOI":"10.1210\/jcem.82.9.4218","article-title":"Alterations in parathyroid dynamics in lithium-treated subjects","volume":"82","author":"Haden","year":"1997","journal-title":"J Clin Endocrinol Metab"},{"key":"2023021305415034500_bvad013-B45","doi-asserted-by":"publisher","first-page":"1785","DOI":"10.2147\/ndt.s86103","article-title":"Effects of maintenance lithium treatment on serum parathyroid hormone and calcium levels: a retrospective longitudinal naturalistic study","volume":"11","author":"Albert","year":"2015","journal-title":"Neuropsychiatr Dis Treat"},{"issue":"1","key":"2023021305415034500_bvad013-B46","doi-asserted-by":"publisher","first-page":"137","DOI":"10.1001\/jamainternmed.2014.5857","article-title":"Association of loop diuretic use with higher parathyroid hormone levels in patients with normal renal function","volume":"175","author":"Corapi","year":"2015","journal-title":"JAMA Intern Med"},{"issue":"2","key":"2023021305415034500_bvad013-B47","doi-asserted-by":"publisher","first-page":"176","DOI":"10.1111\/j.1365-2796.2004.01434.x","article-title":"Effects of long-term treatment with loop diuretics on bone mineral density, calcitropic hormones and bone turnover","volume":"257","author":"Rejnmark","year":"2005","journal-title":"J Intern Med"},{"issue":"10","key":"2023021305415034500_bvad013-B48","doi-asserted-by":"publisher","first-page":"867","DOI":"10.1016\/0026-0495(69)90062-6","article-title":"Thiazide-induced parathyroid","volume":"18","author":"Pickleman","year":"1969","journal-title":"Metab Clin Exp"},{"issue":"2","key":"2023021305415034500_bvad013-B49","doi-asserted-by":"publisher","first-page":"144","DOI":"10.1046\/j.1365-2796.2001.00868.x","article-title":"Effects of thiazide- and loop-diuretics, alone or in combination, on calcitropic hormones and biochemical bone markers: a randomized controlled study","volume":"250","author":"Rejnmark","year":"2001","journal-title":"J Intern Med"},{"issue":"6","key":"2023021305415034500_bvad013-B50","doi-asserted-by":"publisher","first-page":"1137","DOI":"10.1002\/jbmr.2779","article-title":"Parathyroid hormone and the use of diuretics and calcium-channel blockers: the multi-ethnic study of atherosclerosis","volume":"31","author":"Zaheer","year":"2016","journal-title":"J Bone Miner Res"},{"issue":"1","key":"2023021305415034500_bvad013-B51","doi-asserted-by":"publisher","first-page":"23","DOI":"10.1210\/jcem-55-1-23","article-title":"Idiopathic hypercalciuria: hydrochlorothiazide decreases urinary calcium without altered renal response to parathyroid hormone","volume":"55","author":"Van Den Berg","year":"1982","journal-title":"J Clin Endocrinol Metab"},{"issue":"5","key":"2023021305415034500_bvad013-B52","doi-asserted-by":"publisher","first-page":"543","DOI":"10.1042\/cs0750543","article-title":"Changes in calcium metabolic indices during long-term treatment of patients with essential hypertension","volume":"75","author":"Hvarfner","year":"1988","journal-title":"Clin Sci"},{"issue":"9","key":"2023021305415034500_bvad013-B53","doi-asserted-by":"publisher","first-page":"764","DOI":"10.1046\/j.1365-2362.2001.00883.x","article-title":"Loop diuretics alter the diurnal rhythm of endogenous parathyroid hormone secretion. A randomized-controlled study on the effects of loop- and thiazide-diuretics on the diurnal rhythms of calcitropic hormones and biochemical bone markers in postmenopausal","volume":"31","author":"Rejnmark","year":"2001","journal-title":"Eur J Clin Invest"},{"issue":"1","key":"2023021305415034500_bvad013-B54","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.clineuro.2009.10.011","article-title":"Bone and calcium metabolism and antiepileptic drugs","volume":"112","author":"Verrotti","year":"2010","journal-title":"Clin Neurol Neurosurg"},{"issue":"4","key":"2023021305415034500_bvad013-B55","doi-asserted-by":"publisher","first-page":"321","DOI":"10.1097\/mnh.0000000000000505","article-title":"Effects of sodium glucose cotransporter 2 inhibitors on mineral metabolism in type 2 diabetes mellitus","volume":"28","author":"Vinke","year":"2019","journal-title":"Curr Opin Nephrol Hypertens"},{"key":"2023021305415034500_bvad013-B56","doi-asserted-by":"publisher","first-page":"1517","DOI":"10.3389\/fphar.2018.01517","article-title":"Effect of sodium-glucose co-transporter 2 inhibitors on bone metabolism and fracture risk","volume":"9","author":"Ye","year":"2019","journal-title":"Front Pharmacol"},{"issue":"1","key":"2023021305415034500_bvad013-B57","doi-asserted-by":"publisher","first-page":"66","DOI":"10.2215\/cjn.04530418","article-title":"Effects of dapagliflozin on circulating markers of phosphate homeostasis","volume":"14","author":"de Jong","year":"2018","journal-title":"Clin J Am Soc Nephrol"},{"issue":"8","key":"2023021305415034500_bvad013-B58","doi-asserted-by":"publisher","DOI":"10.1172\/jci.insight.99123","article-title":"Canagliflozin triggers the FGF23\/1,25-dihydroxyvitamin D\/PTH axis in healthy volunteers in a randomized crossover study","volume":"3","author":"Blau","year":"2018","journal-title":"JCI Insight"},{"issue":"4","key":"2023021305415034500_bvad013-B59","first-page":"169","article-title":"Proton pump inhibitor-induced hypomagnesaemia and hypocalcaemia: case review","volume":"8","author":"Sivakumar","year":"2016","journal-title":"Int J Physiol Pathophysiol Pharmacol"},{"issue":"10","key":"2023021305415034500_bvad013-B60","doi-asserted-by":"publisher","first-page":"2070","DOI":"10.1111\/jgs.13661","article-title":"Hyperparathyroidism associated with long-term proton pump inhibitors independent of concurrent bisphosphonate therapy in elderly adults","volume":"63","author":"Hinson","year":"2015","journal-title":"J Am Geriatr Soc"},{"issue":"6","key":"2023021305415034500_bvad013-B61","doi-asserted-by":"publisher","first-page":"608","DOI":"10.1258\/0004563011901037","article-title":"Bisphosphonates: an overview with special reference to alendronate","volume":"38","author":"Vasikaran","year":"2001","journal-title":"Ann Clin Biochem"},{"issue":"4","key":"2023021305415034500_bvad013-B62","doi-asserted-by":"publisher","first-page":"499","DOI":"10.1111\/cen.12188","article-title":"Parathyroid hormone changes following denosumab treatment in postmenopausal osteoporosis","volume":"79","author":"Makras","year":"2013","journal-title":"Clin Endocrinol"},{"issue":"1","key":"2023021305415034500_bvad013-B63","doi-asserted-by":"publisher","first-page":"024","DOI":"10.17352\/2455-8591.000033","article-title":"A case of denosumab-associated hyperparathyroidism: a differential diagnostic challenge","volume":"7","author":"Emin","year":"2021","journal-title":"Int J Immunother Cancer Res"},{"issue":"8","key":"2023021305415034500_bvad013-B64","doi-asserted-by":"publisher","first-page":"1397","DOI":"10.1002\/jbmr.3452","article-title":"Effects of 24 months of treatment with romosozumab followed by 12 months of denosumab or placebo in postmenopausal women with low bone mineral density: a randomized, double-blind, phase 2, parallel group study","volume":"33","author":"McClung","year":"2018","journal-title":"J Bone Miner Res"},{"key":"2023021305415034500_bvad013-B65","doi-asserted-by":"publisher","DOI":"10.1016\/j.bonr.2021.101068","article-title":"Real-world effects and adverse events of romosozumab in Japanese osteoporotic patients: a prospective cohort study","volume":"14","author":"Kobayakawa","year":"2021","journal-title":"Bone Rep"},{"issue":"5","key":"2023021305415034500_bvad013-B66","doi-asserted-by":"publisher","first-page":"412","DOI":"10.1056\/nejmoa1305224","article-title":"Romosozumab in postmenopausal women with low bone mineral density","volume":"370","author":"McClung","year":"2014","journal-title":"N Engl J Med"},{"key":"2023021305415034500_bvad013-B67","doi-asserted-by":"publisher","first-page":"969","DOI":"10.1016\/j.biopha.2017.11.037","article-title":"High parathyroid hormone concentration in tenofovir-treated patients are due to inhibition of calcium-sensing receptor activity","volume":"97","author":"Mingione","year":"2018","journal-title":"Biomed Pharmacother"},{"issue":"1","key":"2023021305415034500_bvad013-B68","doi-asserted-by":"publisher","first-page":"15","DOI":"10.1111\/j.1365-2265.1973.tb03480.x","article-title":"Parathyroid function in patients with Paget's disease treated with salmon calcitonin","volume":"2","author":"Burckhardt","year":"1973","journal-title":"Clin Endocrinol"},{"issue":"5","key":"2023021305415034500_bvad013-B69","doi-asserted-by":"publisher","first-page":"1284","DOI":"10.1210\/jcem-71-5-1284","article-title":"Effects of transdermal estrogen replacement on parathyroid hormone secretion","volume":"71","author":"Prince","year":"1990","journal-title":"J Clin Endocrinol Metab"},{"key":"2023021305415034500_bvad013-B70","doi-asserted-by":"publisher","DOI":"10.1155\/2019\/5496710","article-title":"Effects of ferric carboxymaltose on markers of mineral and bone metabolism: a single-center prospective observational study of women with iron deficiency","volume":"141","author":"Frazier","year":"2020","journal-title":"Bone"},{"key":"2023021305415034500_bvad013-B71","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1155\/2019\/5496710","article-title":"Parathyroid hormone measurement in chronic kidney disease: from basics to clinical implications","volume":"2019","author":"Kritmetapak","year":"2019","journal-title":"Int J Nephrol"},{"issue":"6","key":"2023021305415034500_bvad013-B72","doi-asserted-by":"publisher","first-page":"737","DOI":"10.1371\/journal.pone.0226509","article-title":"KDOQI US commentary on the 2017 KDIGO clinical practice guideline update for the diagnosis, evaluation, prevention, and treatment of chronic kidney disease\u2013mineral and bone disorder (CKD-MBD)","volume":"70","author":"Isakova","year":"2017","journal-title":"Am J Kidney Dis"},{"issue":"1","key":"2023021305415034500_bvad013-B73","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0226509","article-title":"Creatinine versus cystatin C for renal function-based mortality prediction in an elderly cohort: the Northern Manhattan Study","volume":"15","author":"Willey","year":"2020","journal-title":"PLoS One"},{"issue":"9","key":"2023021305415034500_bvad013-B74","doi-asserted-by":"publisher","first-page":"912","DOI":"10.1002\/phar.1282","article-title":"Glomerular filtration rate equations overestimate creatinine clearance in older individuals enrolled in the Baltimore Longitudinal Study on Aging: impact on renal drug dosing","volume":"33","author":"Dowling","year":"2013","journal-title":"Pharmacotherapy"},{"issue":"1","key":"2023021305415034500_bvad013-B75","doi-asserted-by":"publisher","first-page":"89","DOI":"10.1007\/s11154-019-09532-w","article-title":"Consensus statement from 2nd international conference on controversies in vitamin D","volume":"21","author":"Giustina","year":"2020","journal-title":"Rev Endocr Metab Disord"},{"issue":"4","key":"2023021305415034500_bvad013-B76","doi-asserted-by":"publisher","first-page":"2122","DOI":"10.1210\/jc.2004-1772","article-title":"Vitamin D repletion in patients with primary hyperparathyroidism and coexistent vitamin D insufficiency","volume":"90","author":"Grey","year":"2005","journal-title":"J Clin Endocrinol Metab"},{"issue":"10","key":"2023021305415034500_bvad013-B77","doi-asserted-by":"publisher","first-page":"1069","DOI":"10.1016\/j.eprac.2022.07.009","article-title":"Calcium challenge to confirm secondary hyperparathyroidism caused by decreased calcium intake","volume":"28","author":"Shokry","year":"2022","journal-title":"Endocr Pract"},{"issue":"4","key":"2023021305415034500_bvad013-B78","doi-asserted-by":"publisher","first-page":"951","DOI":"10.1210\/jcem-70-4-951","article-title":"Suppression of parathyroid hormone secretion with oral calcium in normal subjects and patients with primary hyperparathyroidism","volume":"70","author":"Tohme","year":"1990","journal-title":"J Clin Endocrinol Metab"},{"issue":"18","key":"2023021305415034500_bvad013-B79","doi-asserted-by":"publisher","first-page":"1126","DOI":"10.1056\/nejm198510313131805","article-title":"Sensitivity of the parathyroid hormone\u20131, 25-dihydroxyvitamin D axis to variations in calcium intake in patients with primary hyperparathyroidism","volume":"313","author":"Insogna","year":"1985","journal-title":"N Engl J Med"},{"issue":"7","key":"2023021305415034500_bvad013-B80","doi-asserted-by":"publisher","first-page":"1263","DOI":"10.1002\/jbmr.3992","article-title":"Hyperparathyroidism in patients with X-linked hypophosphatemia","volume":"35","author":"Lecoq","year":"2020","journal-title":"J Bone Miner Res"},{"issue":"4","key":"2023021305415034500_bvad013-B81","doi-asserted-by":"publisher","first-page":"662","DOI":"10.1002\/jbmr.3938","article-title":"Clinical and biochemical phenotypes in a family with ENPP1 mutations","volume":"35","author":"Kotwal","year":"2020","journal-title":"J Bone Miner Res"},{"issue":"1-2","key":"2023021305415034500_bvad013-B82","doi-asserted-by":"publisher","first-page":"150","DOI":"10.1016\/j.cca.2007.08.019","article-title":"False positive PTH results: an easy strategy to test and detect analytical interferences in routine practice","volume":"387","author":"Cavalier","year":"2008","journal-title":"Clinica Chimica Acta"},{"issue":"10","key":"2023021305415034500_bvad013-B83","doi-asserted-by":"publisher","first-page":"2111","DOI":"10.1007\/s00198-021-05950-2","article-title":"Asymptomatic elevated parathyroid hormone level due to immunoassay interference","volume":"32","author":"Zanchetta","year":"2021","journal-title":"Osteoporos Int"},{"issue":"2","key":"2023021305415034500_bvad013-B84","doi-asserted-by":"publisher","first-page":"e8","DOI":"10.4158\/ep10235.cr","article-title":"Falsely elevated plasma parathyroid hormone level mimicking tertiary hyperparathyroidism","volume":"17","author":"Levin","year":"2011","journal-title":"Endocr Pract"},{"issue":"7","key":"2023021305415034500_bvad013-B85","doi-asserted-by":"publisher","first-page":"429","DOI":"10.1055\/a-1856-4900","article-title":"The diagnosis of normocalcaemic hyperparathyroidism is strikingly dissimilar using different commercial laboratory assays","volume":"54","author":"Kalaria","year":"2022","journal-title":"Horm Metab Res"},{"issue":"3","key":"2023021305415034500_bvad013-B86","doi-asserted-by":"publisher","first-page":"287","DOI":"10.1016\/s0039-6060(97)90357-3","article-title":"Population-based screening for primary hyperparathyroidism with serum calcium and parathyroid hormone values in menopausal women","volume":"121","author":"Lundgren","year":"1997","journal-title":"Surgery"},{"issue":"5","key":"2023021305415034500_bvad013-B87","doi-asserted-by":"publisher","first-page":"314","DOI":"10.1590\/s0004-27302011000500003","article-title":"Normocalcemic primary hyperparathyroidism in clinical practice: an indolent condition or a silent threat?","volume":"55","author":"Marques","year":"2011","journal-title":"Arq Bras Endocrinol Metab"},{"issue":"3","key":"2023021305415034500_bvad013-B88","doi-asserted-by":"publisher","first-page":"764","DOI":"10.1007\/s12020-012-9694-z","article-title":"Normocalcemic primary hyperparathyroidism: one-year follow-up in one hundred postmenopausal women","volume":"42","author":"Garc\u00eda-Mart\u00edn","year":"2012","journal-title":"Endocrine"},{"issue":"7","key":"2023021305415034500_bvad013-B89","doi-asserted-by":"publisher","first-page":"2734","DOI":"10.1210\/jc.2013-1300","article-title":"Normocalcemic hyperparathyroidism and hypoparathyroidism in two community-based nonreferral populations","volume":"98","author":"Cusano","year":"2013","journal-title":"J Clin Endocrinol Metab"},{"issue":"2","key":"2023021305415034500_bvad013-B90","doi-asserted-by":"publisher","first-page":"277","DOI":"10.1111\/cen.12819","article-title":"Normocalcaemic, vitamin D-sufficient hyperparathyroidism\u2014high prevalence and low morbidity in the general population: a long-term follow-up study, the WHO MONICA project, Gothenburg, Sweden","volume":"83","author":"Kontogeorgos","year":"2015","journal-title":"Clin Endocrinol"},{"issue":"3","key":"2023021305415034500_bvad013-B91","doi-asserted-by":"publisher","first-page":"359","DOI":"10.1111\/cen.12569","article-title":"Characteristics of hyperparathyroid states in the Canadian Multicentre Osteoporosis Study (CaMos) and relationship to skeletal markers","volume":"82","author":"Berger","year":"2014","journal-title":"Clin Endocrinol"},{"issue":"3","key":"2023021305415034500_bvad013-B92","doi-asserted-by":"publisher","first-page":"172","DOI":"10.1530\/ec-15-0030","article-title":"Normocalcemic primary hyperparathyroidism: a survey in a small village of southern Italy","volume":"4","author":"Vignali","year":"2015","journal-title":"Endocr Connect"},{"issue":"6","key":"2023021305415034500_bvad013-B93","doi-asserted-by":"publisher","first-page":"816","DOI":"10.1111\/cen.12732","article-title":"Normocalcaemic hypoparathyroidism: prevalence and effect on bone status in older women. The OPUS Study","volume":"82","author":"Palermo","year":"2015","journal-title":"Clin Endocrinol"},{"issue":"4","key":"2023021305415034500_bvad013-B94","doi-asserted-by":"publisher","first-page":"243","DOI":"10.1055\/a-0859-1020","article-title":"Normocalcemic primary hyperparathyroidism in adults without a history of nephrolithiasis or fractures: a prospective study","volume":"51","author":"Ros\u00e1rio","year":"2019","journal-title":"Horm Metab Res"},{"issue":"4","key":"2023021305415034500_bvad013-B95","doi-asserted-by":"publisher","first-page":"e1171","DOI":"10.1210\/clinem\/dgaa084","article-title":"Normocalcemic hyperparathyroidism: study of its prevalence and natural history","volume":"105","author":"Schini","year":"2020","journal-title":"J Clin Endocrinol Metab"},{"issue":"11","key":"2023021305415034500_bvad013-B96","doi-asserted-by":"publisher","first-page":"861","DOI":"10.1016\/j.amjmed.2004.06.037","article-title":"Characterization of normocalcemic primary hyperparathyroidism","volume":"117","author":"Tordjman","year":"2004","journal-title":"Am J Med"},{"key":"2023021305415034500_bvad013-B97","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1155\/2012\/128352","article-title":"Normocalcemic versus hypercalcemic primary hyperparathyroidism: more stone than bone?","volume":"2012","author":"Amaral","year":"2012","journal-title":"J Osteoporos"},{"issue":"2","key":"2023021305415034500_bvad013-B98","doi-asserted-by":"publisher","first-page":"419","DOI":"10.1007\/s12020-012-9627-x","article-title":"Investigation of insulin resistance in patients with normocalcemic primary hyperparathyroidism","volume":"42","author":"Cakir","year":"2012","journal-title":"Endocrine"},{"issue":"3","key":"2023021305415034500_bvad013-B99","doi-asserted-by":"publisher","first-page":"294","DOI":"10.4158\/ep15704.or","article-title":"Primary hyperparathyroidism, with a focus on management of the normocalcemic form: to treat or not to treat?","volume":"22","author":"\u0160iprov\u00e1","year":"2016","journal-title":"Endocr Pract"},{"issue":"3","key":"2023021305415034500_bvad013-B100","doi-asserted-by":"publisher","first-page":"331","DOI":"10.1007\/s00774-015-0673-3","article-title":"Normocalcemic hyperparathyroidism is associated with complications similar to those of hypercalcemic hyperparathyroidism","volume":"34","author":"Tuna","year":"2015","journal-title":"J Bone Miner Metab"},{"issue":"11","key":"2023021305415034500_bvad013-B101","doi-asserted-by":"publisher","first-page":"e7","DOI":"10.1055\/a-0799-5387","article-title":"Correction: normocalcemic primary hyperparathyroidism: a comparison with the hypercalcemic form in a tertiary referral population","volume":"50","author":"Pierreux","year":"2018","journal-title":"Horm Metab Res"},{"issue":"7","key":"2023021305415034500_bvad013-B102","doi-asserted-by":"publisher","first-page":"e2609","DOI":"10.1210\/clinem\/dgaa174","article-title":"Clinical, biochemical, and radiological profile of normocalcemic primary hyperparathyroidism","volume":"105","author":"Palermo","year":"2020","journal-title":"J Clin Endocrinol Metab"},{"issue":"5","key":"2023021305415034500_bvad013-B103","doi-asserted-by":"publisher","first-page":"1748","DOI":"10.1210\/jc.2005-2102","article-title":"Effect of primary hyperparathyroidism on volumetric bone mineral density and bone geometry assessed by peripheral quantitative computed tomography in postmenopausal women","volume":"91","author":"Charopoulos","year":"2006","journal-title":"J Clin Endocrinol Metab"},{"issue":"6","key":"2023021305415034500_bvad013-B104","doi-asserted-by":"publisher","first-page":"812","DOI":"10.7326\/m21-4416","article-title":"Mortality and morbidity in mild primary hyperparathyroidism: results from a 10-year prospective randomized controlled trial of parathyroidectomy versus observation","volume":"175","author":"Pretorius","year":"2022","journal-title":"Ann Intern Med"},{"key":"2023021305415034500_bvad013-B105","doi-asserted-by":"publisher","DOI":"10.1016\/j.bone.2020.115583","article-title":"Impaired physical function and evaluation of quality of life in normocalcemic and hypercalcemic primary hyperparathyroidism","volume":"141","author":"Voss","year":"2020","journal-title":"Bone"},{"issue":"5","key":"2023021305415034500_bvad013-B106","doi-asserted-by":"publisher","first-page":"925","DOI":"10.1530\/eje-09-1067","article-title":"Cardiovascular risk factors and arterial rigidity are similar in asymptomatic normocalcemic and hypercalcemic primary hyperparathyroidism","volume":"162","author":"Tordjman","year":"2010","journal-title":"Eur J Endocrinol"},{"key":"2023021305415034500_bvad013-B107","doi-asserted-by":"publisher","first-page":"225","DOI":"10.2147\/vhrm.s128084","article-title":"Evaluation of coronary calcium score in patients with normocalcemic primary hyperparathyroidism","volume":"13","author":"Mesquita","year":"2017","journal-title":"Vasc Health Risk Manag"},{"issue":"1","key":"2023021305415034500_bvad013-B108","doi-asserted-by":"publisher","first-page":"149","DOI":"10.1016\/j.surg.2019.05.094","article-title":"Coronary artery disease is more severe in patients with primary hyperparathyroidism","volume":"167","author":"Koubaity","year":"2020","journal-title":"Surgery"},{"issue":"3","key":"2023021305415034500_bvad013-B109","doi-asserted-by":"publisher","first-page":"971","DOI":"10.1007\/s12020-014-0263-5","article-title":"Investigation of glucose intolerance in patients with normocalcemic primary hyperparathyroidism: 4-year follow-up","volume":"47","author":"Diri","year":"2014","journal-title":"Endocrine"},{"issue":"1","key":"2023021305415034500_bvad013-B110","doi-asserted-by":"publisher","first-page":"23","DOI":"10.4158\/ep14195.or","article-title":"Normocalcemic hyperparathyroidism and insulin resistance","volume":"21","author":"Temizkan","year":"2015","journal-title":"Endocr Pract"},{"issue":"3","key":"2023021305415034500_bvad013-B111","doi-asserted-by":"publisher","first-page":"812","DOI":"10.1007\/s12020-013-0059-z","article-title":"Insulin sensitivity in normocalcaemic primary hyperparathyroidism","volume":"44","author":"Tassone","year":"2013","journal-title":"Endocrine"},{"issue":"1","key":"2023021305415034500_bvad013-B112","doi-asserted-by":"publisher","first-page":"33","DOI":"10.1530\/eje.1.02173","article-title":"Metabolic abnormalities in patients with normocalcemic hyperparathyroidism detected at a population-based screening","volume":"155","author":"Hagstro\u0308m","year":"2006","journal-title":"Eur J Endocrinol"},{"issue":"2","key":"2023021305415034500_bvad013-B113","doi-asserted-by":"publisher","first-page":"111","DOI":"10.1507\/endocrj.ej15-0392","article-title":"Patients with normocalcemic primary hyperparathyroidism may have similar metabolic profile as hypercalcemic patients","volume":"63","author":"Yener Ozturk","year":"2016","journal-title":"Endocr J"},{"issue":"6","key":"2023021305415034500_bvad013-B114","doi-asserted-by":"publisher","first-page":"2420","DOI":"10.1210\/jc.2014-4432","article-title":"Is normocalcemic primary hyperparathyroidism harmful or harmless?","volume":"100","author":"Chen","year":"2015","journal-title":"J Clin Endocrinol Metab"},{"key":"2023021305415034500_bvad013-B115","doi-asserted-by":"publisher","DOI":"10.1016\/j.diabres.2019.107985","article-title":"Increased parathyroid hormone is associated with higher fasting glucose in individuals with normocalcemic primary hyperparathyroidism and prediabetes: a pilot study","volume":"160","author":"Karras","year":"2020","journal-title":"Diabetes Res Clin Pract"},{"issue":"11","key":"2023021305415034500_bvad013-B116","doi-asserted-by":"publisher","first-page":"3522","DOI":"10.3390\/nu12113522","article-title":"Improving glucose homeostasis after parathyroidectomy for normocalcemic primary hyperparathyroidism with co-existing prediabetes","volume":"12","author":"Karras","year":"2020","journal-title":"Nutrients"},{"issue":"2","key":"2023021305415034500_bvad013-B117","doi-asserted-by":"publisher","first-page":"539","DOI":"10.1245\/s10434-018-6998-0","article-title":"Biochemical and skeletal outcomes of parathyroidectomy for normocalcemic (incipient) primary hyperparathyroidism","volume":"26","author":"Sho","year":"2018","journal-title":"Ann Surg Oncol"},{"issue":"11","key":"2023021305415034500_bvad013-B118","doi-asserted-by":"publisher","first-page":"2373","DOI":"10.1002\/jbmr.4689","article-title":"Surgical aspects of primary hyperparathyroidism","volume":"37","author":"Perrier","year":"2022","journal-title":"J Bone Mineral Res"},{"issue":"4","key":"2023021305415034500_bvad013-B119","doi-asserted-by":"publisher","first-page":"493","DOI":"10.1111\/1754-9485.12728","article-title":"Better performance of four-dimension computed tomography as a localization procedure in normocalcemic primary hyperparathyroidism","volume":"62","author":"Cunha-Bezerra","year":"2018","journal-title":"J Med Imaging Radiat Oncol"},{"issue":"6","key":"2023021305415034500_bvad013-B120","doi-asserted-by":"publisher","first-page":"831","DOI":"10.1111\/cen.14667","article-title":"Normocalcemic primary hyperparathyroidism: 99mTc SestaMibi SPECT\/CT results compare with hypercalcemic hyperparathyroidism","volume":"96","author":"Musumeci","year":"2022","journal-title":"Clin Endocrinol (Oxf)"},{"issue":"4","key":"2023021305415034500_bvad013-B121","doi-asserted-by":"publisher","first-page":"992","DOI":"10.1007\/s00268-018-4512-2","article-title":"Classic primary hyperparathyroidism versus normocalcemic and normohormonal variants: do they really differ?","volume":"42","author":"Kiriakopoulos","year":"2018","journal-title":"World J Surg"},{"issue":"1","key":"2023021305415034500_bvad013-B122","doi-asserted-by":"publisher","first-page":"70","DOI":"10.1016\/j.surg.2016.08.054","article-title":"Differences in single gland and multigland disease are seen in low biochemical profile primary hyperparathyroidism","volume":"161","author":"Lim","year":"2017","journal-title":"Surgery"},{"issue":"1","key":"2023021305415034500_bvad013-B123","doi-asserted-by":"publisher","first-page":"168","DOI":"10.1016\/j.surg.2019.06.043","article-title":"Normocalcemic hyperparathyroidism: a collaborative endocrine surgery quality improvement program analysis","volume":"167","author":"Pandian","year":"2020","journal-title":"Surgery"},{"issue":"10","key":"2023021305415034500_bvad013-B124","doi-asserted-by":"publisher","first-page":"4473","DOI":"10.1210\/jc.2019-00705","article-title":"Persistently elevated PTH after parathyroidectomy at one year: experience in a tertiary referral center","volume":"104","author":"Caldwell","year":"2019","journal-title":"J Clin Endocrinol Metab"},{"issue":"3","key":"2023021305415034500_bvad013-B125","doi-asserted-by":"publisher","first-page":"659","DOI":"10.1007\/s00405-017-4836-9","article-title":"Elevated parathyroid hormone levels after successful parathyroidectomy for primary hyperparathyroidism: a clinical review","volume":"275","author":"de la Plaza Llamas","year":"2017","journal-title":"Eur Arch Otorhinolaryngol"},{"issue":"1","key":"2023021305415034500_bvad013-B126","doi-asserted-by":"publisher","first-page":"120","DOI":"10.1016\/j.surg.2020.05.049","article-title":"Early biochemical response to parathyroidectomy for primary hyperparathyroidism and its predictive value for recurrent hypercalcemia and recurrent primary hyperparathyroidism","volume":"169","author":"Ryder","year":"2021","journal-title":"Surgery"},{"key":"2023021305415034500_bvad013-B127","doi-asserted-by":"publisher","first-page":"57","DOI":"10.4158\/ep10324.ra","article-title":"Significance of elevated parathyroid hormone after parathyroidectomy for primary hyperparathyroidism","volume":"17","author":"Oltmann","year":"2011","journal-title":"Endocr Pract"},{"issue":"17","key":"2023021305415034500_bvad013-B128","doi-asserted-by":"publisher","first-page":"1249","DOI":"10.1056\/nejm199910213411701","article-title":"A 10-year prospective study of primary hyperparathyroidism with or without parathyroid surgery","volume":"341","author":"Silverberg","year":"1999","journal-title":"N Engl J Med"},{"issue":"9","key":"2023021305415034500_bvad013-B129","doi-asserted-by":"publisher","first-page":"3462","DOI":"10.1210\/jc.2007-1215","article-title":"The natural history of primary hyperparathyroidism with or without parathyroid surgery after 15 years","volume":"93","author":"Rubin","year":"2008","journal-title":"J Clin Endocr Metab"},{"issue":"11","key":"2023021305415034500_bvad013-B130","doi-asserted-by":"publisher","first-page":"5415","DOI":"10.1210\/jc.2004-0028","article-title":"Randomized controlled clinical trial of surgery versus no surgery in patients with mild asymptomatic primary hyperparathyroidism","volume":"89","author":"Rao","year":"2004","journal-title":"J Clin Endocrinol Metab"},{"issue":"8","key":"2023021305415034500_bvad013-B131","doi-asserted-by":"crossref","first-page":"3114","DOI":"10.1210\/jc.2007-0219","article-title":"Surgery or surveillance for mild asymptomatic primary hyperparathyroidism: a prospective randomized clinical trial","volume":"92","author":"Ambrogini","year":"2007","journal-title":"J Clin Endocrinol Metab"},{"issue":"5","key":"2023021305415034500_bvad013-B132","doi-asserted-by":"crossref","first-page":"1687","DOI":"10.1210\/jc.2006-1836","article-title":"Medical observation, compared with parathyroidectomy, for asymptomatic primary hyperparathyroidism: a prospective, randomized trial","volume":"92","author":"Bollerslev","year":"2007","journal-title":"J Clin Endocrinol Metab"},{"issue":"9","key":"2023021305415034500_bvad013-B133","doi-asserted-by":"publisher","first-page":"1907","DOI":"10.1002\/jbmr.3177","article-title":"Effect of surgery versus observation: skeletal 5-year outcomes in a randomized trial of patients with primary HPT (the SIPH study)","volume":"32","author":"Lundstam","year":"2017","journal-title":"J Bone Miner Res"},{"issue":"4","key":"2023021305415034500_bvad013-B134","doi-asserted-by":"publisher","first-page":"1359","DOI":"10.1210\/jc.2014-3441","article-title":"Effects of parathyroidectomy versus observation on the development of vertebral fractures in mild primary hyperparathyroidism","volume":"100","author":"Lundstam","year":"2015","journal-title":"J Clin Endocrinol Metab"},{"issue":"9","key":"2023021305415034500_bvad013-B135","doi-asserted-by":"publisher","first-page":"885","DOI":"10.1001\/archsurg.141.9.885","article-title":"The effect of parathyroidectomy on bone fracture risk in patients with primary hyperparathyroidism","volume":"141","author":"VanderWalde","year":"2006","journal-title":"Arch Surg"},{"issue":"7261","key":"2023021305415034500_bvad013-B136","doi-asserted-by":"publisher","first-page":"598","DOI":"10.1136\/bmj.321.7261.598","article-title":"Cohort study of risk of fracture before and after surgery for primary hyperparathyroidism","volume":"321","author":"Vestergaard","year":"2000","journal-title":"BMJ"},{"issue":"3","key":"2023021305415034500_bvad013-B137","doi-asserted-by":"publisher","first-page":"276","DOI":"10.1111\/cen.14703","article-title":"Reduced fracture incidence in patients having surgery for primary hyperparathyroidism","volume":"97","author":"Nilsson","year":"2022","journal-title":"Clin Endocrinol (Oxf)"},{"issue":"8","key":"2023021305415034500_bvad013-B138","doi-asserted-by":"publisher","first-page":"3213","DOI":"10.1210\/jc.2013-1518","article-title":"Bone mineral density evolution after successful parathyroidectomy in patients with normocalcemic primary hyperparathyroidism","volume":"98","author":"Koumakis","year":"2013","journal-title":"J Clin Endocrinol Metab"},{"issue":"1","key":"2023021305415034500_bvad013-B139","doi-asserted-by":"publisher","first-page":"106","DOI":"10.1186\/s12872-019-1093-4","article-title":"Parathyroidectomy improves cardiovascular risk factors in normocalcemic and hypercalcemic primary hyperparathyroidism","volume":"19","author":"Beysel","year":"2019","journal-title":"BMC Cardiovasc Disord"},{"issue":"3","key":"2023021305415034500_bvad013-B140","doi-asserted-by":"publisher","first-page":"223","DOI":"10.1002\/bjs.10739","article-title":"Effect of parathyroidectomy on quality of life and non-specific symptoms in normocalcaemic primary hyperparathyroidism","volume":"105","author":"Bannani","year":"2018","journal-title":"Br J Surg"},{"issue":"7","key":"2023021305415034500_bvad013-B141","doi-asserted-by":"publisher","first-page":"3319","DOI":"10.1210\/jc.2003-030908","article-title":"Alendronate in primary hyperparathyroidism: a double-blind, randomized, placebo-controlled trial","volume":"89","author":"Khan","year":"2004","journal-title":"J Clin Endocrinol Metab"},{"issue":"7","key":"2023021305415034500_bvad013-B142","doi-asserted-by":"publisher","first-page":"705","DOI":"10.4158\/ep08178.orr","article-title":"Alendronate therapy in men with primary hyperparathyroidism","volume":"15","author":"Khan","year":"2009","journal-title":"Endocr Pract"},{"key":"2023021305415034500_bvad013-B143","doi-asserted-by":"crossref","first-page":"113","DOI":"10.1359\/jbmr.2001.16.1.113","article-title":"Effects of oral alendronate in elderly patients with osteoporosis and mild primary hyperparathyroidism","volume":"16","author":"Rossini","year":"2001","journal-title":"J Bone Miner Res"},{"issue":"2","key":"2023021305415034500_bvad013-B144","doi-asserted-by":"publisher","first-page":"581","DOI":"10.1210\/jc.2002-020890","article-title":"Oral alendronate increases bone mineral density in postmenopausal women with primary hyperparathyroidism","volume":"88","author":"Chow","year":"2003","journal-title":"J Clin Endocrinol Metab"},{"issue":"4","key":"2023021305415034500_bvad013-B145","doi-asserted-by":"publisher","first-page":"1295","DOI":"10.1007\/s00198-014-3000-2","article-title":"Effects of alendronate and vitamin D in patients with normocalcemic primary hyperparathyroidism","volume":"26","author":"Cesareo","year":"2014","journal-title":"Osteoporos Int"},{"issue":"1","key":"2023021305415034500_bvad013-B146","doi-asserted-by":"publisher","first-page":"66","DOI":"10.4081\/aiua.2015.1.66","article-title":"Use of cinacalcet in nephrolithiasis associated with normocalcemic or hypercalcemic primary hyperparathyroidism: results of a prospective randomized pilot study","volume":"87","author":"Brardi","year":"2015","journal-title":"Arch Ital Urol Androl"},{"issue":"3","key":"2023021305415034500_bvad013-B147","doi-asserted-by":"publisher","first-page":"679","DOI":"10.1007\/s12020-020-02276-7","article-title":"The calcium-to-phosphorous (Ca\/P) ratio in the diagnosis of primary hyperparathyroidism and hypoparathyroidism: a multicentric study","volume":"68","author":"Madeo","year":"2020","journal-title":"Endocrine"},{"issue":"1","key":"2023021305415034500_bvad013-B148","doi-asserted-by":"publisher","first-page":"5","DOI":"10.1186\/s12902-019-0487-8","article-title":"New parathyroid function index for the differentiation of primary and secondary hyperparathyroidism: a case-control study","volume":"20","author":"Guo","year":"2020","journal-title":"BMC Endocr Disord"}],"container-title":["Journal of the Endocrine Society"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/jes\/article-pdf\/7\/4\/bvad013\/49164156\/bvad013.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/jes\/article-pdf\/7\/4\/bvad013\/49164156\/bvad013.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,2,13]],"date-time":"2023-02-13T05:42:08Z","timestamp":1676266928000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/jes\/article\/doi\/10.1210\/jendso\/bvad013\/7005424"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,1,26]]},"references-count":148,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2023,2,9]]}},"URL":"https:\/\/doi.org\/10.1210\/jendso\/bvad013","relation":{},"ISSN":["2472-1972"],"issn-type":[{"value":"2472-1972","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2023,4,1]]},"published":{"date-parts":[[2023,1,26]]},"article-number":"bvad013"}}